-
Signature
-
/s /Drew Parkes, Attorney-in-Fact for Cannon-Brookes Michael
-
Issuer symbol
-
TEAM
-
Transactions as of
-
26 Sep 2025
-
Net transactions value
-
-$1,266,697
-
Form type
-
4
-
Filing time
-
29 Sep 2025, 17:37:51 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| Cannon-Brookes Michael |
CEO, Co-Founder, Director, 10%+ Owner |
C/O ATLASSIAN CORPORATION, 350 BUSH STREET, FLOOR 13, SAN FRANCISCO |
/s /Drew Parkes, Attorney-in-Fact for Cannon-Brookes Michael |
29 Sep 2025 |
0001666120 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
TEAM |
Class A Common Stock |
Sale |
$524,703 |
-3,170 |
-14% |
$165.52 |
19,825 |
26 Sep 2025 |
See Footnote |
F1, F2, F3 |
| transaction |
TEAM |
Class A Common Stock |
Sale |
$72,916 |
-450 |
-2.3% |
$162.04 |
19,375 |
26 Sep 2025 |
See Footnote |
F1, F3, F4 |
| transaction |
TEAM |
Class A Common Stock |
Sale |
$336,150 |
-2,018 |
-10% |
$166.58 |
17,357 |
26 Sep 2025 |
See Footnote |
F1, F3, F5 |
| transaction |
TEAM |
Class A Common Stock |
Sale |
$262,903 |
-1,600 |
-9.2% |
$164.31 |
15,757 |
26 Sep 2025 |
See Footnote |
F1, F3, F6 |
| transaction |
TEAM |
Class A Common Stock |
Sale |
$8,357 |
-50 |
-0.32% |
$167.14 |
15,707 |
26 Sep 2025 |
See Footnote |
F1, F3 |
| transaction |
TEAM |
Class A Common Stock |
Sale |
$61,668 |
-377 |
-2.4% |
$163.58 |
15,330 |
26 Sep 2025 |
See Footnote |
F1, F3, F7 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: